Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/06 – EX-12.(B)

On: Tuesday, 6/26/07, at 1:06pm ET · For: 12/31/06 · Accession #: 897069-7-1446 · File #: 1-12033

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/26/07  Nymox Pharmaceutical Corp         20-F       12/31/06    5:1.0M                                   Foley & Lardner/FA

Annual Report of a Foreign Private Issuer — Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report                                       HTML    951K 
 2: EX-12.(A)   Statement re: Computation of Ratios                 HTML     10K 
 3: EX-12.(B)   Statement re: Computation of Ratios                 HTML     10K 
 4: EX-13.(A)   Annual or Quarterly Report to Security Holders      HTML      6K 
 5: EX-13.(B)   Annual or Quarterly Report to Security Holders      HTML      6K

EX-12.(B) — Statement re: Computation of Ratios

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

CERTIFICATION

I, Roy Wolvin, certify that:

1.	I have reviewed this annual report on Form 20-F of Nymox Pharmaceutical Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.	The company’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) for the company and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosures and procedures, as of the end of the period covered by this report based on such evaluation; and

c) disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.	The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of company’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: June 26, 2007

/s/ Roy Wolvin
Roy Wolvin
Chief Financial Officer
Nymox Pharmaceutical Corporation

Dates Referenced Herein and Documents Incorporated by Reference

This ‘20-F’ Filing	Date	Other Filings

Filed on:	6/26/07
For Period End:	12/31/06	6-K
		List all Filings

↑Top

Filing Submission 0000897069-07-001446 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)